Urs Rohner - GlaxoSmithKline PLC Non-Executive Independent Director
| GSK Stock | USD 33.70 0.35 1.05% |
Director
Mr. Urs Rohner is NonExecutive Independent Director of GlaxoSmithKline PLC. Urs has a broad range of business and legal experience having served as Chairman on a number of Boards, most recently for Credit Suisse, a worldleading financial services company. Prior to joining Credit Suisse in 2004, Urs served as Chairman of the Executive Board and CEO of ProSieben and ProSiebenSat.1 Media AG. This followed a number of years in private practice at major law firms in Switzerland and the US, having been admitted to the bars of the canton of Zurich in Switzerland in 1986 and the state of New York in the US in 1990. Urs is Chairman of the Board of Credit Suisse Group AG and of its Chairmans and Governance Committee. He is also Chairman and member of the Board of Trustees of Credit Suisse Research Institute and Credit Suisse Foundation. Urs was appointed ViceChairman of the Governing Board of the Swiss Bankers Association in 2015. since 2015.
| Age | 60 |
| Tenure | 9 years |
| Address | 980 Great West Road, Brentford, United Kingdom, TW8 9GS |
| Phone | 44 20 8047 5000 |
| Web | https://www.gsk.com |
GlaxoSmithKline PLC Management Efficiency
The company has Return on Asset of 0.0724 % which means that on every $100 spent on assets, it made $0.0724 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2185 %, implying that it generated $0.2185 on every 100 dollars invested. GlaxoSmithKline PLC's management efficiency ratios could be used to measure how well GlaxoSmithKline PLC manages its routine affairs as well as how well it operates its assets and liabilities. At this time, GlaxoSmithKline PLC's Return On Tangible Assets are quite stable compared to the past year. Return On Assets is expected to rise to 0.15 this year, although the value of Return On Capital Employed will most likely fall to 0.17. Change To Liabilities is expected to rise to about 596.5 M this year, although the value of Total Current Liabilities will most likely fall to about 11.2 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Marc Dunoyer | AstraZeneca PLC ADR | 72 | |
| Mark McClellan | Johnson Johnson | 57 | |
| Kathy Warden | Merck Company | 49 | |
| Robert Bertolini | Bristol Myers Squibb | 58 | |
| Patricia Russo | Merck Company | 68 | |
| Nancy Andrews | Novartis AG ADR | 63 | |
| Vicki Sato | Bristol Myers Squibb | 71 | |
| Glenn Tilton | AbbVie Inc | 72 | |
| Melody Meyer | AbbVie Inc | 63 | |
| Ian Davis | Johnson Johnson | 70 | |
| Leslie Brun | Merck Company | 68 | |
| Sherilyn McCoy | AstraZeneca PLC ADR | 60 | |
| Deborah DiSanzo | AstraZeneca PLC ADR | 59 | |
| Michael Bonney | Bristol Myers Squibb | 61 | |
| Frans Houten | Novartis AG ADR | 61 | |
| Dinesh Paliwal | Bristol Myers Squibb | 63 | |
| Mary Beckerle | Johnson Johnson | 66 | |
| Paul Rothman | Merck Company | 63 | |
| Roxanne Austin | AbbVie Inc | 60 | |
| Manuel Medina | Bristol Myers Squibb | 53 | |
| Jennifer Doudna | Johnson Johnson | 57 | |
Management Performance
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.0724 |
GlaxoSmithKline PLC ADR Leadership Team
Elected by the shareholders, the GlaxoSmithKline PLC's board of directors comprises two types of representatives: GlaxoSmithKline PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlaxoSmithKline. The board's role is to monitor GlaxoSmithKline PLC's management team and ensure that shareholders' interests are well served. GlaxoSmithKline PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlaxoSmithKline PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lynn Elsenhans, Independent Non-Executive Director | ||
| Luke Miels, President - Global Pharmaceuticals | ||
| Hal Barron, Chief Scientific Officer, President - Research & Development, Executive Director | ||
| Harry Dietz, Non-Executive Independent Director, Scientific and Medical Expert | ||
| Emma Walmsley, Chief Executive Officer, Executive Director | ||
| CA BSc, President Development | ||
| Philip Thomson, President Affairs | ||
| Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare | ||
| Charles Bancroft, Non-Executive Independent Director | ||
| Vivienne Cox, Independent Non-Executive Director and Workforce Engagement Director | ||
| Diana Conrad, Senior Vice President - Human Resources | ||
| Roger Connor, President - Global Manufacturing & Supply | ||
| Phil Thomson, Senior Vice President - Global Communications | ||
| Judy Lewent, Non-Executive Independent Director | ||
| Shobie Ramakrishnan, Chief Digital and Technology Officer | ||
| Sarah EltonFarr, Head Relations | ||
| Julie Brown, Chief Officer | ||
| Urs Rohner, Non-Executive Independent Director | ||
| Marvinder Banga, Senior Non-Executive Independent Director | ||
| Anne Beal, Non-Executive Independent Director | ||
| Jesse Goodman, Non-Executive Independent Director and Scientific and Medical Expert | ||
| Laurie Glimcher, Non-Executive Independent Director and Scientific & Medical Expert | ||
| Julie ACA, CFO Director | ||
| Nick Hirons, Senior Vice President - Global Ethics and Compliance | ||
| Sally Jackson, Senior Vice President - Global Communications and CEO Office | ||
| James Ford, Senior Vice President, Group General Counsel, Legal and Compliance | ||
| Victoria Whyte, Company Secretary | ||
| Tony Wood, Chief Scientific Officer - Designate | ||
| David Redfern, Chief Strategy Officer | ||
| Regis Simard, President - Pharmaceutical Supply Chain | ||
| Jonathan Symonds, Independent Non-Executive Chairman of the Board | ||
| Iain Mackay, Chief Financial Officer, Executive Director | ||
| Karenann Terrell, Chief Digital and Technology Officer | ||
| Deborah Waterhouse, Chief Executive Officer - ViiV Healthcare |
GlaxoSmithKline Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GlaxoSmithKline PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.0724 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 83.87 B | ||||
| Shares Outstanding | 2.04 B | ||||
| Shares Owned By Insiders | 0.06 % | ||||
| Shares Owned By Institutions | 15.37 % | ||||
| Number Of Shares Shorted | 16.29 M | ||||
| Price To Earning | 11.80 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.28) | Dividend Share 0.61 | Earnings Share 1.54 | Revenue Per Share 15.38 | Quarterly Revenue Growth (0.02) |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.